Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.87 |
| ▸ | PLK3 | Q9H4B4 | 14/20 | 0.87 |
| ▸ | PLK2 | Q9NYY3 | 13/20 | 0.87 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.85 |
| ▸ | CLK2 | P49760 | 3/20 | 0.85 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.85 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.85 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.85 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.85 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.85 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.85 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.85 |
| ▸ | PRKCG | P05129 | 2/20 | 0.85 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.85 |
| ▸ | NEK4 | P51957 | 2/20 | 0.85 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.85 |
| ▸ | BRD4 | O60885 | 6/20 | 0.81 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.81 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.81 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16971992 | 1.00 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL29453442 | 1.00 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL376134 | 1.00 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL15257514 | 0.99 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL30356851 | 0.94 | PLK1 (0.81) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL31098099 | 0.94 | PLK1 (0.81) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL12825254 | 0.94 | PLK1 (0.84) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL12323284 | 0.94 | PLK1 (0.85) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL14215917 | 0.93 | PLK1 (0.80) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL30325075 | 0.93 | PLK1 (0.86) | PLK1PLK3PLK2PRKD3CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2024054954-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-116396295-A | Synthesis method of PLK1 degradation agent based on PROTAC | 合肥工业大学 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023059583-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023059605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023059581-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| CN-108350062-B | Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy | 达纳-法伯癌症研究所股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | AURKB, CDK9, AURKA | PLK1 9/4885PLK3 519/4885PLK2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.